Haemophilia is a collective term describing rare, usually inherited genetic blood coagulation disorders that lead to abnormally long bleeding at the site of wound or injury and, in severe cases, spontaneous bleeding episodes without any apparent injury. The disorders are caused by absent or insufficient activity of blood coagulation factors.

This report covers the two main types of the disease, haemophilia A (factor VIII deficiency) and B (factor IX deficiency), both of which are X-linked recessive disorders that are much more common in males, as well as acquired haemophilia, a very rare autoimmune disorder caused by abnormal immune system autoreactivity, resulting in clotting factor deficiency (usually factor VIII) and signs and symptoms similar to those of HA/HB.

This report provides the current prevalent population for haemophilia across 17 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Greece, Turkey, Russia, Japan, China, India, Australia, Brazil, Mexico) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, sub-populations with the covered types of haemophilia, as well as several of the main symptoms and co-morbidities of haemophilia and clinical features thereof have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for haemophilia include:

  • Development of inhibitors
  • Haemophilic arthropathy
  • Reduced bone density
  • Cirrhosis
  • Hepatocellular carcinoma

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in global haemophilia market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of haemophilia and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on haemophilia prevalent population.
  • Identify sub-populations within haemophilia which require treatment.
  • Gain an understanding of the specific markets that have the largest number of haemophilia patients.